

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

29 May 2026

### Clinical trial of the effect of aqueous extract of *Salvia mirzayani* in control of blood sugar of type 2 diabetic patients in comparison with control group

#### Protocol summary

##### Summary

The purpose of this study is to evaluate the effect of aqueous extract of *Salvia mirzayani* on the control of blood sugar in Type 2 diabetic patients. In this study, 58 Type 2 diabetic patients refer to diabetes clinic of Shahid Mohammadi Hospital, are divided into interventional and control groups. The interventional group receives capsules containing 450 mg of concentrated aqueous extract of *Salvia mirzayani* and the control group receives placebo capsules containing 450 mg of caramelized flour and 5% of aqueous extract of *Salvia mirzayani*. The inclusion criteria include patients with the age range between 19 and 65 years, who have BMI higher than 19 and lower than 30, patients with HbA1C higher than 7% and blood sugar higher than 126 mg/d. The exclusion criteria include pregnant women, patients with active infection or hepatitis, patients with blood pressure higher than 160/90 and cancer. The patients' demographic information such as age, sex, height, weight, body mass index, types and dosage of used drugs will be collected. The tests including determination of FBS, HbA1C, liver enzymes, lipid profile and serum insulin will be conducted at the beginning of the study and after 3 months. Serum will be separated from 5cc blood of fasting patients and the mentioned measurements will be performed and the results will be compared in the interventional and control groups. This clinical trial is double blind (neither the administrator nor the subject know which subjects receive a real drug or placebo).

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015122725712N1**  
Registration date: **2017-04-27, 1396/02/07**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2017-04-27, 1396/02/07

##### Registrant information

###### Name

Soheila Moein

###### Name of organization / entity

Hormozgan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 763668476

###### Email address

smoein@sums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice chancellor for Research, Hormozgan University of Medical Sciences

##### Expected recruitment start date

2016-04-03, 1395/01/15

##### Expected recruitment end date

2016-07-05, 1395/04/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Clinical trial of the effect of aqueous extract of *Salvia mirzayani* in control of blood sugar of type 2 diabetic

patients in comparison with control group

### Public title

Investigation the effect of aqueous extract of salvia mirzayanii in treatment of diabetes

### Purpose

Treatment

### Inclusion/Exclusion criteria

Inclusion criteria include patients with the age range between 19 and 65 years; patients having diabetes mellitus based on the guideline of the WHO 1999; Patients with BMI were >19 Kg/m<sup>2</sup> and <30 Kg/m<sup>2</sup>; Patients with BMI > 30, who have not any other diseases; Patients without insulin therapy and any other complications; Patients with HbA1C > 7% and blood sugar > 7 mmol/l Exclusion criteria's include pregnant women, or women wanted to become Pregnant; Patients with active infections or hepatitis C, B, HIV or TB (or in TB therapy); Cancer patients (except patients with skin cancer); patients using steroids such as prednisone for the treatment of a chronic disease; patients smoking cigarettes and drinking alcohol; patients with blood pressure higher than 160/90; usage of contraceptive pill by women; Moreover, patients with malabsorption; chronic diarrhea; liver and kidney diseases; ischemia heart failure; anemia; heart attack; peripheral vascular disease and diabetic nephropathy are excluded from the study.

### Age

From **19 years** old to **65 years** old

### Gender

Both

### Phase

2

### Groups that have been masked

*No information*

### Sample size

Target sample size: **58**

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Double blinded

### Blinding description

### Placebo

Used

### Assignment

Parallel

### Other design features

in the beginning of the study and after 3 months of intervention, randomization will be performed by using random number table

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

### Name of ethics committee

Ethics committee of Hormozgan University of Medical Sciences

### Street address

Pardis of Hormozgan University of Medical Sciences , Emam Hossein BLVd, Bandarabbas

### City

Bandarabbas

### Postal code

### Approval date

2015-09-23, 1394/07/01

### Ethics committee reference number

HUMS.REC.1394.53

## Health conditions studied

### 1

#### Description of health condition studied

Type 2 diabetes disease based on WHO guide line

#### ICD-10 code

E11

#### ICD-10 code description

Non insulin dependent diabetes

## Primary outcomes

### 1

#### Description

HbA1C

#### Timepoint

in the beginnig of study and after 3 months of intervention

#### Method of measurement

by kit

### 2

#### Description

levels of liver enzymes

#### Timepoint

beginning of the study and after 3 months of intervention

#### Method of measurement

by kit

### 3

#### Description

lipid profile

#### Timepoint

beginning of the study and after 3 months of intervention

#### Method of measurement

by kit

### 4

#### Description

Fasting Blood Sugar(FBS)

#### Timepoint

in the beginnig of the study and after 3 months of intervention

## Method of measurement

by kit

## Secondary outcomes

### 1

#### Description

BMI

#### Timepoint

in the beginning of the study and after 3 months of intervention

#### Method of measurement

Balance

## Intervention groups

### 1

#### Description

Interventional group: Every day one hour after lunch, patients of interventional group receive 1 capsule containing 450 mg of aqueous extract of *Salvia mirzayanii* for 3 months.

#### Category

Placebo

### 2

#### Description

Control group: Every day one hour after lunch, patients of this group receive 1 placebo capsule containing 450 mg of caramelized flour and 5% of aqueous extract of *Salvia mirzayanii* for 3 months.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

diabetes clinic

##### Full name of responsible person

Leila Bahmanzadeh

##### Street address

Shahid Mohammadi Hospital

##### City

Bandarabbas

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Hormozgan University of Medical Sciences

##### Full name of responsible person

Dr Aghamolaei

##### Street address

Vice chancellor for Research, Hormozgan University of Medical Sciences, Shahid Mohammadi Hospital

##### City

Bandarabbas

##### Grant name

-

##### Grant code / Reference number

94102

##### Is the source of funding the same sponsor organization/entity?

Yes

##### Title of funding source

Hormozgan University of Medical Sciences

##### Proportion provided by this source

100

##### Public or private sector

empty

##### Domestic or foreign origin

empty

##### Category of foreign source of funding

empty

##### Country of origin

##### Type of organization providing the funding

empty

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Hormozgan University of Medical Sciences

#### Full name of responsible person

Dr Soheila Moein

#### Position

Research assistant, Ph.D, Associate Professor

#### Other areas of specialty/work

#### Street address

Faculty of Medicine, Pardis of Hormozgan University of Medical Sciences, Emam Hossein BLVd

#### City

Bandarabbas

#### Postal code

7919693116

#### Phone

+98 76 3366 8476

#### Fax

+98 76 3366 8478

#### Email

soheila\_9@yahoo.com; smoein@razi.tums.ac.ir

#### Web page address

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Hormozgan University of Medical Sciences

#### Full name of responsible person

Soheila Moein

#### Position

Research assistant, Ph.D, associate professor

#### Other areas of specialty/work

#### Street address

Faculty of Medicine, Pardis of Hormozgan University  
of Medical Sciences, Emam Hossein BLVd

**City**

Bandarabbas

**Postal code**

7919693116

**Phone**

+98 76 3366 8476

**Fax**

+98 76 3366 8478

**Email**

soheila\_9@yahoo.com; smoein@razi.tums.ac.ir

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Hormozgan University of Medical Sciences

**Full name of responsible person**

Rahman Mehdizadeh

**Position**

Research Ph.d candidate

**Other areas of specialty/work**

**Street address**

Faculty of Medicine, Pardis of Hormozgan University  
of Medical Sciences, Emam Hossein BLVd

**City**

Bandarabbas

**Postal code**

7919693116

**Phone**

+98 76 3366 8476

**Fax**

+98 76 3366 8476

**Email**

rahman.biochem@gmail.com

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*